Physicians' Academy for Cardiovascular Education
Meeting Impression | PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies

Meeting Impression | PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies

August 26, 2017 - ESC

See below to download the Meeting Impression

The role of PCSK9 inhibitors as a novel strategy to reduce LDL-c was addressed in this educational program chaired by Wolfgang Koenig and Michel Farnier at the ESC Congress 2017 in Barcelona, Spain. John Chapman, Kees Hovingh, and Peter Sever discussed the need for additional LDL-c lowering therapies in patients with familial hypercholesterolemia (FH) and the mechanisms and potential applications of therapies, including PCSK9-based therapies, to lower LDL-c in combination with statins or without in statin-intolerant patients. Moreover, evidence from recent trials of novel agents, the need for outcomes data from clinical trials, and the implications of new therapies for future management were presented.

Educational information

The educational objectives of this symposium were to:

Faculty

Disclosures

This satellite symposium was organised by the PACE Foundation and sponsored by an unrestricted educational grant of Amgen and Sanofi-Regeneron.

Download Meeting Impression View lectures - PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies